

DT09 Rec'd PCT/PTO 23 JUN 2004

00/500040

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	USNP of PCT/EP02/12533
Filing Date	8 November 2002 (08.11.2002)
First Named Inventor	H. EGGENWEILER et al.
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	MERCK-2893

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
SM	001	4,229,453		Roth, et al.	10-21-1980
SM	002	5,328,910		Rodney B. Hargreaves	07-12-1994

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	003	EP	0605205		Troponwerke GmbH & Co.	11-14-1979		
	004	EP	0482804		ICI PLC	04-20-1993		
	005	DE	3145287		Troponwerke GmbH & Co.	05-10-1999		
	006	WO	94 13070		PFIZER INC.	06-23-1994		
	007	WO	0157025		Pfizer Products Inc.	06-09-2001		
	008	WO	0130040		Merck Patent GmbH	04-20-2001		
	009	WO	0134601		Merck Patent GmbH	05-17-2001		
	010	WO	0132618		Merck Patent GmbH	05-10-2001		

Examiner
Signature

/Susanna Moore/

Date
Considered

05/25/2006

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DT09 Rec'd PTO 23 JUN 2004
10/500040

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	USNP of PCT/EP02/12533
Filing Date	8 November 2002 (08.11.2002)
First Named Inventor	H. EGGENWEILER et al.
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	MERCK-2893

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	011	K. EGGER ET AL. "Selected Reactions on the o-Aminonitrile System of Substituted Pyrroles" J. HETEROCYCL. CHEM., Bd. 24, Nr. 2, 1987	
	012	C.F. MUELLER ET AL. "7-Deaza-2-phenyladenines: Structure Activity Relationships of Potent A1 Selective Receptor Antagonists" J. MED. CHEM., Bd. 33, Nr. 10, 1990	
	013	M. ADENOT ET AL. "Interest of cluster significance analysis in structure-affinity relationships for non-xanthine heterocyclic antagonists of adenosine" EUR. J. MED. CHEM Bd. 32, Nr. 6, 1997	
	014	A. MIYASHITA ET AL. "Preparation of heteroarene carbonitriles by reaction of heteroarenes with potassium cyanide catalyzed by sodium p-toluenesulfinate" HETEROCYCLES, Bd. 39, Nr. 1, 1994	
	015	G. FOLKERS, H.-D. HOLTJE "Active site molecular modelling of xanthine oxidase inhibitors with anti-inflammatory activity" J MOLECULAR GRAPHICS, Bd. 3, Nr. 4, 1985	
	016	D. STEINBILBER ET AL. "New Class of 5-Lipoxygenase Inhibitors: Correlation Between Inhibition of LTB4 Production and Chemiluminescence of Human Polymorphonuclear Granulocytes" PHARM. RESEARCH Bd. 3, Nr. 5, 1986	
	017	F. JOHANNSEN ET AL. "Reactions of Heterocyclic o-Aminonitriles with Acetic Formic Anhydride" CHEMICA SCRIPTA, Bd. 26, Nr. 2, 1986	
	018	H. J. ROTH, K. EGGER "Synthesen von Pyrrolo-2,3-dipyrimidinen" ARCH. PHARMAZ., Bd. 888, Nr. 4, 1975	
	019	J.W. DALY ET AL. "7-Deaza-9-phenyladenines. A new class of adenosine receptor antagonists" BIOCHEM. PHARMACOL., Bd. 37, Nr. 19, 1988	
	020	A.O. ABDEL HAMID ET AL. "Reactions with heterocyclic o-aminonitriles: synthesis of pyrrolo-2,3-bipyridine, pyrrolo-2,3-dipyrimidine and pyrrole derivatives" HETEROCYCLES, Bd. 27, Nr. 8, 1988	
	021	S. KLUMPP ET AL. "Pyrrolo-2,3-dipyrimidines as inhibitors of cAMP Phosphodiesterases" BIOCHEM. PHARMACOL., Bd. 38, Nr. 6, 1989	
	022	A. MIYASHITA ET AL. "Catalytic Action of Azolium Salts. IX. Synthesis of 6-Aroyl-OH-purines and Their Analogues by Nucleophilic Aroylation Catalyzed by Imidazolium or Benzimidazolium Salt" CHEM. PHARM. BULL., Bd. 46, Nr. 3, 1998	
	023	G. FOLKERO "Rezeptoraffinität von Xanthinoxidase-Inhibitoren strukturelle Voraussetzungen" DEUTSCHE APOTHEKER ZEITUNG, Bd. 126, Nr. 41, 1986	

Examiner
Signature

/Susanna Moore/

Date not
Considered

05/25/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.